| Literature DB >> 34977183 |
Shenglei Shu1,2, Cheng Wang3, Ziming Hong4, Xiaoyue Zhou5, Tianjng Zhang6, Qinmu Peng4, Jing Wang1,2, Chuansheng Zheng1,2.
Abstract
Background: Late enhanced cardiac magnetic resonance (CMR) images of the left ventricular myocardium contain an enormous amount of information that could provide prognostic value beyond that of late gadolinium enhancements (LGEs). With computational postprocessing and analysis, the heterogeneities and variations of myocardial signal intensities can be interpreted and measured as texture features. This study aimed to evaluate the value of texture features extracted from late enhanced CMR images of the myocardium to predict adverse outcomes in patients with dilated cardiomyopathy (DCM) and severe systolic dysfunction.Entities:
Keywords: cardiac magnetic resonance; dilated cardiomyopathy; prognosis; survival; texture features
Year: 2021 PMID: 34977183 PMCID: PMC8718517 DOI: 10.3389/fcvm.2021.766423
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flowchart of textures extraction and selection.
Figure 2Flowchart of patients selection.
Baseline clinical characteristics.
|
|
|
|
| |
|---|---|---|---|---|
|
| ||||
| Age, years | 47.5 (35.8, 57.0) | 56.0 (36.0, 59.0) | 47.0 (33.5, 56.0) | 0.280 |
| Female, | 37 (32.5%) | 7 (24.1%) | 30 (35.3%) | 0.268 |
| BMI (kg/m2) | 24.1 (21.0, 26.4) | 22.5 (19.3, 25.3) | 24.6 (21.4, 26.7) | 0.027 |
| Family history | 13 (11.4%) | 2 (6.9%) | 11 (12.9%) | 0.51 |
| Hypertension, | 23 (20.2%) | 4 (13.8%) | 19 (22.4%) | 0.426 |
| Diabetes mellitus, | 16 (14.0%) | 6 (20.7%) | 10 (11.8%) | 0.232 |
| Tobacco, | 39 (34.2%) | 9 (31.0%) | 30 (35.3%) | 0.821 |
| Alcohol, | 20 (17.5%) | 5 (17.2%) | 15 (17.6%) | >0.99 |
| Dyslipidemia, | 17 (14.9%) | 5 (17.2%) | 12 (14.1%) | 0.764 |
| SBP (mmHg) | 115 (102, 130) | 100 (94, 114) | 121 (109, 135) | <0.001 |
| DBP (mmHg) | 72 (64, 88) | 65 (60, 74) | 77 (67, 88) | 0.005 |
|
| ||||
| I, | 1 (0.9%) | 0 (0%) | 1 (1.3%) | 0.007 |
| II, | 29 (27.1%) | 7 (24.1%) | 22 (28.2%) | |
| III, | 47 (43.9%) | 7 (24.1%) | 40 (51.3%) | |
| IV, | 30 (28.0%) | 15 (51.7%) | 15 (19.2%) | |
|
| ||||
| Heart rate (bpm) | 89 (72, 100) | 76 (67, 97) | 89 (74, 101) | 0.210 |
| AVB, | 3 (2.7%) | 1 (3.6%) | 2 (2.4%) | >0.99 |
| LBBB, | 15 (13.6%) | 4 (14.3%) | 11 (13.4%) | >0.99 |
| RBBB, | 4 (3.6%) | 1 (3.6%) | 3 (3.7%) | >0.99 |
| QRS duration (ms) | 100.0 (91.5, 116.5) | 106.0 (100.0, 132.0) | 100.0 (90.0, 110.0) | 0.021 |
| QTc interval (ms) | 438.5 (413.75, 466.5) | 450 (420, 485) | 436 (412.25, 464.5) | 0.163 |
|
| ||||
| Beta-blockers, | 87 (76.3%) | 18 (62.1%) | 69 (81.2%) | 0.037 |
| ACEI/ARB, | 35 (30.7%) | 11 (37.9%) | 24 (28.2%) | 0.328 |
| Diuretics, | 43 (37.7%) | 15 (51.7%) | 28 (32.9%) | 0.072 |
| Spironolactone, | 74 (64.9%) | 21 (72.4%) | 53 (62.4%) | 0.327 |
| Digoxin, | 37 (32.5%) | 10 (34.5%) | 27 (31.8%) | 0.787 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, new york heart association; AVB, atrioventricular block; LBBB, left branch bundle block; RBBB, right branch bundle block; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blockers.
Baseline cardiac magnetic resonance (CMR) parameters.
|
|
|
|
|
|
|---|---|---|---|---|
| LV EF (%) | 14.0 (10.7, 19.2) | 13.7 (11.0, 19.2) | 14.9 (10.3, 19.5) | 0.873 |
| LV EDVI (ml/m2) | 175.8 (147.7, 214.2) | 161.6 (133.8, 203.1) | 185.4 (150.8, 219.0) | 0.116 |
| LV ESVI (ml/m2) | 149.4 (120.5, 191.5) | 148.4 (110.8, 176.0) | 154.2 (124.5, 195.8) | 0.218 |
| LV mass index (g/m2) | 88.6 (74.6, 105.8) | 89.5 (77.0, 95.8) | 88.1 (73.7, 109.0) | 0.977 |
| RV EF (%) | 18.8 (9.3, 33.3) | 29.8 (14.2, 38.1) | 16.0 (8.5, 29.0) | 0.034 |
| RV EDVI (ml/m2) | 88.7 (65.3, 114.4) | 89.7 (64.3, 115.8) | 88.7 (65.6, 113.0) | 0.925 |
| RV ESVI (ml/m2) | 66.0 (46.4, 94.6) | 65.7 (43.7, 92.4) | 66.2 (51.6, 96.6) | 0.382 |
| Presence of LGE, | 95 (83.3%) | 27 (93.1%) | 68 (80.0%) | 0.149 |
| LGE location | 0.203 | |||
| Absent | 19 (16.7%) | 2 (6.9%) | 17 (20%) | |
| Only septal LGE | 10 (8.8%) | 2 (6.9%) | 8 (9.4%) | |
| Only free-wall LGE | 4 (3.5%) | 0 (0.0%) | 4 (4.7%) | |
| Septal & free-wall LGE | 81 (71.1%) | 25 (86.2%) | 56 (65.9%) | |
| LGE extent | 2.21 (0.68, 4.86) | 3.65 (1.29, 11.13) | 1.61 (0.51, 3.09) | 0.001 |
CMR, cardiac magnetic resonance; LV, left ventricle; EF, ejection fraction; EDVI, indexed end-diastolic volume; ESVI, indexed end-systolic volume; RV, right ventricle; LGE, late gadolinium enhancement.
Characteristics of employed texture features for survival analysis.
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
| |||
| GLCM_contrast | It is a measure of the local intensity variation, favoring values away from the diagonal. | 20.923 | 24.719 | 19.881 | 0.007 |
| GLCM_difference average | It measures the relationship between occurrences of pairs with similar intensity values and occurrences of pairs with differing intensity values. | 3.275 | 3.502 | 3.216 | 0.011 |
| GLCM_difference entropy | It is a measure of the randomness/variability in neighborhood intensity value differences. | 3.260 | 3.361 | 3.235 | 0.007 |
IQR, Interquartile range; GLCM, gray-level co-occurrence matrix.
Univariable Cox regression analysis of baseline clinical variables.
|
|
|
| |
|---|---|---|---|
|
| |||
| Age, years | 0.940 | 0.973–1.030 | 0.940 |
| Gender (Female) | 1.528 | 0.652–3.582 | 0.329 |
| BMI (kg/m2) | 0.892 | 0.836–0.925 | 0.001 |
| Hypertension | 0.600 | 0.208–1.725 | 0.343 |
| Diabetes mellitus | 1.533 | 0.624–3.767 | 0.352 |
| Tobacco | 0.906 | 0.412–1.991 | 0.806 |
| Alcohol | 0.953 | 0.363–2.501 | 0.922 |
| Dyslipidemia | 1.263 | 0.482–3.312 | 0.635 |
| SBP (mmHg) | 0.953 | 0.930–0.976 | 0.000 |
| DBP (mmHg) | 0.963 | 0.936–0.990 | 0.008 |
| NYHA function class | 2.03 | 1.36–3.04 | 0.000 |
|
| |||
| Heart rate (bpm) | 0.988 | 0.970–1.008 | 0.233 |
| AVB | 1.531 | 0.208–11.296 | 0.676 |
| LBBB | 1.123 | 0.389–3.241 | 0.830 |
| RBBB | 1.235 | 0.167–9.150 | 0.836 |
| QRS duration (ms) | 1.011 | 0.998–1.024 | 0.096 |
| QTc interval (ms) | 1.003 | 0.997–1.009 | 0.366 |
|
| |||
| Beta-blockers | 0.393 | 0.183–0.841 | 0.016 |
| ACEI/ARB | 1.301 | 0.610–2.779 | 0.496 |
| Diuretics | 2.154 | 1.038–4.469 | 0.035 |
| Spironolactone | 1.590 | 0.703–3.594 | 0.265 |
| Digoxin | 1.064 | 0.494–2.291 | 0.875 |
|
| |||
| LV EF (%) | 0.999 | 0.945–1.056 | 0.963 |
| LV EDVI (ml/m2) | 0.996 | 0.990–1.002 | 0.224 |
| LV ESVI (ml/m2) | 0.996 | 0.990–1.003 | 0.257 |
| LV mass index (g/m2) | 0.999 | 0.986–1.012 | 0.849 |
| RV EF (%) | 1.025 | 1.000–1.050 | 0.046 |
| RV EDVI (ml/m2) | 0.998 | 0.987–1.009 | 0.752 |
| RV ESVI (ml/m2) | 0.994 | 0.983–1.005 | 0.283 |
| LGE presence | 3.247 | 0.771–13.680 | 0.109 |
| LGE location | 1.513 | 0.991–2.310 | 0.055 |
| LGE extent | 1.070 | 1.039–1.102 | 0.000 |
|
| |||
| GLCM_contrast | 1.072 | 1.031–1.114 | 0.000 |
| GLCM_difference average | 2.482 | 1.424–4.327 | 0.001 |
| GLCM_difference entropy | 12.748 | 2.692–60.371 | 0.001 |
HR, hazard ratio; CI, confidence interval and the rest abbreviations are same as those in .
Figure 3Kaplan-Meier curves for late gadolinium enhancement (LGE) extent (A), gray-level cooccurrence matrix (GLCM)_contrast (B), GLCM_difference average (C), and GLCM_difference entropy (D). For each texture feature, median value was chosen to divide the entire patient population into two parts. Statistical difference between curves was measured using the log-rank test.
Multivariable Cox regression analysis incorporating texture features.
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| SBP | 0.960 | 0.002 | 0.961 | 0.002 | 0.961 | 0.002 |
| LGE extent | 1.051 | 0.004 | 1.050 | 0.004 | 1.049 | 0.005 |
| GLCM_contrast | 1.061 | 0.010 | – | – | – | – |
| GLCM_difference average | – | – | 2.151 | 0.022 | – | – |
| GLCM_difference entropy | – | – | – | – | 7.645 | 0.025 |
HR, hazard ratio; CI, confidence interval.